10 Things Worth Pay...
Ariad Pharmaceuticals (ARIA: NASDAQ)
$15.63 -0.08 | -0.51%
06/04/12 - 04:00 PM ET
Company Balance Sheet
| Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | |
| Assets | ||||
|---|---|---|---|---|
| Cash and Equivalents | 306.26M | 103.63M | 40.36M | 24.24M |
| Receivables | 34.00K | 407.00K | 3.58M | 0.00 |
| Inventories | 0.00 | 0.00 | 1.95M | 4.06M |
| Other Current Assets | 1.28M | 1.14M | 0.00 | 5.58M |
| Total Current Assets | 307.57M | 105.17M | 45.90M | 48.70M |
| Property, Plant & Equipment, Gross | 39.98M | 37.76M | 37.57M | 37.00M |
| Accumulated Depreciation & Depletion | 33.37M | 30.73M | 28.83M | 27.40M |
| Property, Plant & Equipment, Net | 6.61M | 7.04M | 8.74M | 9.59M |
| Intangibles | 5.74M | 7.07M | 9.63M | 9.87M |
| Other Non-Current Assets | 791.00K | 749.00K | 749.00K | 26.00K |
| Total Non-Current Assets | 13.14M | 14.86M | 19.11M | 19.48M |
| Liabilities & Shareholder Equity | ||||
| Total Assets | 320.71M | 120.03M | 65.01M | 68.19M |
| Accounts Payable | 5.73M | 3.12M | 4.81M | 9.37M |
| Short Term Debt | 1.45M | 1.47M | 11.67M | 1.47M |
| Other Current Liabilities | 1.17M | 829.00K | 787.00K | 941.00K |
| Total Current Liabilities | 25.37M | 16.40M | 37.68M | 34.53M |
| Long Term Debt | 11.22M | 8.29M | 142.00K | 11.55M |
| Deferred Income Taxes | 2.72M | 2.12M | 1.36M | 0.00 |
| Other Non-Current Liabilities | 61.26M | 29.14M | 114.84M | 91.24M |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Non-Current Liabilities | 75.20M | 39.56M | 116.34M | 102.86M |
| Total Liabilities | 100.57M | 55.95M | 154.03M | 137.39M |
| Preferred Stock Equity | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Stock Equity | 220.14M | 64.08M | -89.02M | -69.20M |
| Common Par | 158.00K | 127.00K | 109.00K | 71.00K |
| Additional Paid In Capital | 776.95M | 497.31M | 429.48M | 369.31M |
| Cumulative Translation Adjustment | 0.00 | 0.00 | 0.00 | 0.00 |
| Retained Earnings | -556.96M | -433.36M | -518.61M | -438.60M |
| Treasury Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Equity Adjustments | 0.00 | 0.00 | 0.00 | 18.00K |
| Total Capitalization | 231.36M | 72.37M | -88.87M | -57.65M |
| Total Equity | 220.14M | 64.08M | -89.02M | -69.20M |
| Total Liabilities & Stock Equity | 320.71M | 120.03M | 65.01M | 68.19M |
| Total Common Shares Outstanding | 157.61M | 126.94M | 109.04M | 71.37M |
| Preferred Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Treasury Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic Weighted Shares Outstanding | 132.38M | 113.02M | 93.33M | 69.79M |
| Diluted Weighted Shares Outstanding | 132.38M | 114.73M | 93.33M | 69.79M |
| Number of Employees | 150 | 122 | 149 | 150 |
| Number of Part-Time Employees | 0 | 0 | 0 | 0 |
Portfolios with ARIA
- Portfolio NameUser Type
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- Contributor7 Cancer Drug Stocks to Kno...
- ContributorStocks At New 52-Week Highs...
- ContributorStocks Rising On Unusual Vo...
- Contributor10 Biotech Stocks Loved and...
- ContributorEarnings Short Squeeze Play...
- Contributor5 Stocks Under-$10 Setting ...
- Userlance and donna
- ContributorHot Biotech Trades for Seco...
Latest ARIA Headlines from TheStreet
- ASCO 2012 Live Blog -- Monday 06.04.12 | 06:06 am
- ASCO '12: Ariad Pharma Leukemia Drug Posts Improved Response Rates 06.04.12 | 12:06 am
- Biotech Stock Mailbag: ASCO, Celldex, Obesity Drug Game-Changer 05.25.12 | 05:05 am
- The Next Big Thing in Biotech: ASCO Conference
05.25.12 | 05:05 am - ASCO '12 Abstract Dump: Cancer Stocks in Focus (Update) 05.17.12 | 06:05 am
- ASCO '12 Abstract Dump: Cancer Stocks in Focus 05.16.12 | 06:05 pm
- Ariad Stock Hits New 52-Week High (ARIA) 05.11.12 | 01:05 pm
- Ariad Reaches New 52-Week High (ARIA) 04.27.12 | 11:04 am
- Endocyte Shares Rise on Merck Cancer Deal 04.16.12 | 09:04 am
- Analysts' Actions: ARIA, EA, HGSI, BBBY 04.12.12 | 08:04 am
Press Releases for ARIA
- ARIAD Announces Updated Data From Pivotal PACE Trial Of Ponatinib, Its Investigational Pan-BCR-ABL Inhibitor - Business Wire 06.04.12 | 07:06 am
- ARIAD To Present At Upcoming Investor Conferences - Business Wire 05.30.12 | 07:05 am
- ARIAD To Present At Bank Of America Merrill Lynch 2012 Health Care Conference - Business Wire 05.10.12 | 07:05 am
- ARIAD To Present At The Deutsche Bank 37th Annual Health Care Conference - Business Wire 04.30.12 | 07:04 am
- ARIAD To Webcast Conference Call On First Quarter 2012 Financial Results - Business Wire 04.25.12 | 07:04 am
- ARIAD Presents New Preclinical Data On Ponatinib And AP26113 - Business Wire 04.02.12 | 09:04 am
- ARIAD Announces Presentations Of Preclinical Data At American Association For Cancer Research Annual Meeting - Business Wire 03.26.12 | 07:03 am
- Merck And ARIAD Pharmaceuticals Provide Update On FDA Advisory Committee Vote On Investigational Medicine Ridaforolimus For The Treatment Of Metastatic Soft-Tissue Or Bone Sarcomas - Business Wire 03.20.12 | 07:03 pm
- ARIAD To Present At Barclays Capital Global Healthcare Conference - Business Wire 03.06.12 | 07:03 am
- ARIAD Reports 2011 Financial Results And Outlines Key Development And Commercialization Plans For 2012 - Business Wire 02.28.12 | 07:02 am
Partner Headlines for ARIA
- AACR Annual Oncology Meeting: A Look Into Various Abstracts - Seeking Alpha 03.27.12 | 09:03 am
- Zacks #5 Rank Additions for Thursday - Tale of the Tape - Zacks 03.22.12 | 09:03 am
- Zacks #5 Rank Additions for Wednesday - Tale of the Tape - Zacks 03.14.12 | 09:03 am
- Zacks #5 Rank Additions for Tuesday - Tale of the Tape - Zacks 02.28.12 | 09:02 am
- Notable Put Options Activity in ARIAD Pharmaceuticals - Benzinga 02.02.12 | 01:02 pm
- Biotech Equities Continue To Benefit From Discoveries And Acquisitions In 2012 - Seeking Alpha 01.27.12 | 09:01 am
- 10 Stocks That Made New Highs On Friday: Hedging Costs - Seeking Alpha 01.15.12 | 07:01 am
- Using Friday's Option Trades To Find Investment Ideas - Seeking Alpha 01.13.12 | 06:01 pm
- YM's Positive Results Have Incyte Investors Worried - Seeking Alpha 12.15.11 | 09:12 am
- Rodman & Renshaw Maintain Market Outperform Rating and $15 PT on ARIAD Pharmaceuticals - Benzinga 11.01.11 | 09:11 am





